Although inhibitors of glycolytic flux have been proposed as potential approach for cancer therapy, high toxicity in highly glucose-dependent tissues such as the brain, retina or testes have been identified as a major challenge.9 Therefore, we concentrated our studies on the remaining hypoxia-sensitizing screening hits that displayed a phenotype different from GLUT or glycolysis inhibitors and induced hypoxia-specific cell death by a potential novel mode of action. Here, SLC2A1 is linked to cancer.